M T Luetmer1, D F Kallmes. 1. College of Saint Benedict/Saint John's University, St. Joseph, Minnesota, USA.
Abstract
BACKGROUND AND PURPOSE: Our aim was to determine whether referral patterns and rates of vertebroplasties at the Mayo Clinic have changed after the publication of the INVEST and the Australian Trial. In August of 2009, we performed a retrospective review of patients undergoing vertebroplasties and those patients who were referred for but did not receive vertebroplasties before and after the recently published placebo-controlled vertebroplasty trials. MATERIALS AND METHODS: After approval by our local institutional review board, we retrospectively evaluated all patients referred for vertebroplasty between January 5, 2004, and June 2, 2010. We catalogued age, sex, number of treated vertebrae, physician referring the patient for vertebroplasty, and the referring department. We calculated the mean number of referrals per month before and after August 2009, which was the month of publication for both trials. We also calculated rates for specific referring physician types. RESULTS: During the full study, 1188 patients were referred, of whom 807 underwent treatment at 1378 levels for a total of 943 separate vertebroplasty procedures. The mean number of vertebroplasty referrals per month has dropped significantly from 18.9 ± 5.3 (95% CI, 17.7-20.2) before publication to 11.3 ± 3.1 (95% CI, 9.1-13.5) referrals per month after publication (P=.0001). Before publication, 67.3 ± 14.0% (95% CI, 64.0%-70.7%) of patients referred for vertebroplasty underwent vertebroplasty, compared with 76.0 ± 14.9% (95% CI, 65.4%-86.6%) after publication (P=.11). CONCLUSIONS: The number of vertebroplasty referrals at our center has decreased significantly since the publication of INVEST and the Australian Trial, yet we continue to offer the procedure to a high proportion of referred patients.
BACKGROUND AND PURPOSE: Our aim was to determine whether referral patterns and rates of vertebroplasties at the Mayo Clinic have changed after the publication of the INVEST and the Australian Trial. In August of 2009, we performed a retrospective review of patients undergoing vertebroplasties and those patients who were referred for but did not receive vertebroplasties before and after the recently published placebo-controlled vertebroplasty trials. MATERIALS AND METHODS: After approval by our local institutional review board, we retrospectively evaluated all patients referred for vertebroplasty between January 5, 2004, and June 2, 2010. We catalogued age, sex, number of treated vertebrae, physician referring the patient for vertebroplasty, and the referring department. We calculated the mean number of referrals per month before and after August 2009, which was the month of publication for both trials. We also calculated rates for specific referring physician types. RESULTS: During the full study, 1188 patients were referred, of whom 807 underwent treatment at 1378 levels for a total of 943 separate vertebroplasty procedures. The mean number of vertebroplasty referrals per month has dropped significantly from 18.9 ± 5.3 (95% CI, 17.7-20.2) before publication to 11.3 ± 3.1 (95% CI, 9.1-13.5) referrals per month after publication (P=.0001). Before publication, 67.3 ± 14.0% (95% CI, 64.0%-70.7%) of patients referred for vertebroplasty underwent vertebroplasty, compared with 76.0 ± 14.9% (95% CI, 65.4%-86.6%) after publication (P=.11). CONCLUSIONS: The number of vertebroplasty referrals at our center has decreased significantly since the publication of INVEST and the Australian Trial, yet we continue to offer the procedure to a high proportion of referred patients.
Authors: David F Kallmes; Bryan A Comstock; Patrick J Heagerty; Judith A Turner; David J Wilson; Terry H Diamond; Richard Edwards; Leigh A Gray; Lydia Stout; Sara Owen; William Hollingworth; Basavaraj Ghdoke; Deborah J Annesley-Williams; Stuart H Ralston; Jeffrey G Jarvik Journal: N Engl J Med Date: 2009-08-06 Impact factor: 91.245
Authors: Rachelle Buchbinder; Richard H Osborne; Peter R Ebeling; John D Wark; Peter Mitchell; Chris Wriedt; Stephen Graves; Margaret P Staples; Bridie Murphy Journal: N Engl J Med Date: 2009-08-06 Impact factor: 91.245
Authors: K F Layton; K R Thielen; C A Koch; P H Luetmer; J I Lane; J T Wald; D F Kallmes Journal: AJNR Am J Neuroradiol Date: 2007-04 Impact factor: 3.825
Authors: C Kasperk; P J Meeder; G Nöldge; B Wiedenhöfer; R Ewerbeck; H Bardenheuer; I Grafe; F-X Huber; P Nawroth Journal: Exp Clin Endocrinol Diabetes Date: 2010-01-26 Impact factor: 2.949
Authors: Roberto Luigi Cazzato; Teodora Bellone; Marco Scardapane; Pierre De Marini; Pierre-Alexis Autrusseau; Pierre Auloge; Julien Garnon; Jack W Jennings; Afshin Gangi Journal: Eur Radiol Date: 2021-04-26 Impact factor: 5.315
Authors: Jeanna Parsons Leigh; Emma E Sypes; Sharon E Straus; Danielle Demiantschuk; Henry Ma; Rebecca Brundin-Mather; Chloe de Grood; Emily A FitzGerald; Sara Mizen; Henry T Stelfox; Daniel J Niven Journal: BMC Health Serv Res Date: 2022-04-06 Impact factor: 2.655
Authors: Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox Journal: BMC Med Date: 2015-10-06 Impact factor: 8.775